Skip to main content
FULC logo

FULC

Fulcrum Therapeutics, Inc.
$3.72 -0.12 (-3.13%) At close · Jul 6
Market Cap
$247.88M
Shares
66,633,321

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$0 -100%
FY2025 Revenue FY2020–FY2025
Net Income
-$74.88M -669.6%
FY2025 Net Income FY2018–FY2025
Operating Margin
-27.37% +3917.9pp
FY2024 Operating Margin FY2020–FY2024
Diluted EPS
-$1.18 -637.5%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
-$60.07M -2608.1%
FY2025 Operating Cash Flow FY2018–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
$0 $80M $2.81M $6.34M $19.16M $8.82M
$56.78M $56.1M $63.39M $71.8M $76.78M $69.7M $59.04M $71.07M $25.18M
$29.77M $28.67M $36.45M $41.67M $41.69M $30.52M $21.39M $13.15M $8.31M
$400K $1.7M $400K
$86.55M $84.77M $101.9M $113.47M $118.9M $100.22M $80.43M $84.22M $33.5M
-$86.55M -$84.77M -$21.9M -$110.66M -$112.56M -$81.05M -$71.61M -$84.22M -$33.5M
-27.37% -3945.24% -1774.85% -422.97% -811.64%
$0 $0
-$76.12M -$74.88M -$9.73M -$97.34M -$109.87M -$80.85M -$70.82M -$82.68M -$32.59M
-12.16% -3470.23% -1732.43% -421.89% -802.66%
-$70.82M -$89.81M -$39.15M
-$76.7M -$74.84M -$9.46M -$96.67M -$110.27M -$81.24M -$70.82M -$82.68M
USD/shares -$1.18 -$0.16 -$1.59 -$2.44 -$2.29 -$2.79
USD/shares -$1.18 -$0.16 -$1.59 -$2.44 -$2.29 -$2.79
shares 63.36K 61.98K 61.31K 44.99K 35.36K 25.35K 11.05K 1257
shares 63.36K 61.98K 61.31K 44.99K 35.36K 25.35K 11.05K 1257
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Key facts CIK 1680581 CUSIP 359616109 13F (30d) 3 filings 3 filers Visit website Investor relations